

10th European Congress of the European Opiate Addiction Treatment Association May 25-27, 2012

Barcelo' Sants, Barcelona, Spain, EU www.europad.org

Preliminary programme

Friday, May 25 2012

Room: A - Pre-Congress Oral Presentations

Special Event - Research Reports Chairman I. Maremmani (Pisa, Italy.)

- 12:00 MARTA TORRENS (Barcelona, Spain) 20 years of MMTP in Spain: past and present
- 12:30 INMACULADA RIVAS (Barcelona, Spain) Cumulated experience of the MMTP in metropolitan Barcelona-1992-2010
- 13:00 FRANCISCO GONZALEZ-SAIZ (Cadiz, Spain) Clinical assessment of opiate induction: The Opiate Dosage Adequacy Scale (O.D.A.S.-IF)
- 13:30 STEPHAN WALCHER (Munich, Germany) Preliminary results of Methode Study in Germany

Room: A - Pre-Congress Oral Presentations

- I Voluntary discontinuation of OMT an insufficiently studied option Chairman H. Waal (Oslo Norway)
- 15:00 HELGE WAAL (Oslo, Norway) Voluntary discontinuation of OMT: Should it be encouraged and how should it be done? An analysis of the evidence
- 15:30 THOMAS CLAUSEN and HELGE WAAL (Oslo, Norway) To end an OMT program participation: a risky undertaking. Evidence from longitudinal studies
- 16:00 LINE EIKENES (Oslo, Norway) Detoxified and happy
- 16:30 AMBROS UCHTENHAGEN (Zurich, Switzerland) Maturing out of heroin use? Ex users voluntarily abstinent after participation in heroin assisted treatment

Room: B - Pre-Congress Oral Presentations

- II Drug related deaths and psychopathology in Slovenian heroin addictsChairman R. Tavčar (Ljubljana Slovenia)
- 15:00 ROK TAVČAR (Ljubljana, Slovenia) Drug related deaths and psychopathology in Slovenian heroin addicts
- 15:30 JOZICA SEMERL SELB (Ljubljana, Slovenia) Drug related deaths in Slovenia
- 16:00 BARBARA LOVRECIC (Ljubljana, Slovenia) Suicides among all illicit drug related deaths

16:30 MERCEDES LOVRECIC (Ljubljana, Slovenia) - Anxiety-depressive mental status in heroin addicts entering treatment

Room: C - Pre-Congress Oral Presentations

III - EUROPAD Hot Topics

Chairman I. Maremmani (Pisa - Italy)

- 14:00 HAIM MELL (Jerusalem, Israel) Support groups online (by video conference) for opiate addicts in recovery
- 14:30 BODIL MONWELL (Jönköping, Sweden) Target group for OST: Validating patient drug history
- 15:00 NEIL MACKEGANEY (Glasgow, Scotland, UK) From harm reduction to Recovery
- 15:30 DAVID BEST (Melbourne, Australia) From harm reduction to recovery: not such a massive leap?
- 16:00 PASCAL COURTY (Clermont Ferrand, France) How to establish a good therapeutic
- 16:30 DUNCAN CAIRNS (London, England) Therapeutic alliance from a patient's perspective

Room: A - Plenary Session

Chairman I. Maremmani (Pisa - Italy) and M. Casas (Barcelona - Spain)

- 17:00 MARK PARRINO (New York, USA) Medication Assisted Treatment for Opioid Addiction: Challenges and Opportunities
- 17:30 LORETTA P. FINNEGAN (Avalon, USA) Pregnancy and heroin addiction: forty years of research and clinical experiences
- 18:30 ROBERT NEWMAN (New York, USA) Maintenance treatment of addiction 40 years later: a glass half-full.... and half empty

Saturday, May 26 2012

Room: A - Plenary Session

Chairman M. Reisinger (Brussels - Belgium)

9:30 MIGUEL CASAS (Barcelona, Spain)) – The self-medication hypothesis in opiate addiction

Room: A - Parallel Symposia

IV - Heroin Addiction and Related Clinical Problems Chairman I. Maremmani (Pisa - Italy)

- 11:00 RICHARD SOYER (Linz, Austria) Cost economy: Public health costs versus law enforcement costs in opiate addiction
- 11:30 EUGENE KRUPITSKY (St. Petersburg, Russia) Naltrexone for opioid dependence: oral, implantable and injectable
- 12:00 NATALIA V. BARANOK (Murmansk, Russia) Behavioral intervention aimed to treat co-dependence in relatives of opiate addicts improves treatment outcomes
- 12:30 ROBERT LUBRAN (Rockville, USA) A Global Update on Medication Assisted Treatment for Heroin and Opioid Dependence

Room: B - Parallel Symposia

V - New perspectives in the opiate-dependent patient's treatment Chairman M. Casas (Barcelona - Spain)

- 11:00 MIGUEL CASAS (Barcelona, Spain) The evolution of the Maintenance Programs with opiate in Spain
- 11:30 CARLOS RONCERO (Barcelona, Spain) Psychotic symptoms in opiate self-injectors vs cocaine self-injectors in a harm reduction program
- 12:00 GIDEONI FUSTE (Barcelona, Spain) Severity of addiction and follow-up in opiate-dependent patients.
- 12:30 JOAN COLOM (Barcelona, Spain) New proposal of maintenance of opiate addicts with oral diacetylmorphine

Room: C - Parallel Symposia

VI - Psychological strategies and interventions in the treatment of opiate addiction Chairman A. Kantchelov (Sofia - Bulgaria)

- 11:00 ALEXANDER KANTCHELOV (Sofia, Bulgaria) Partnership with the patient as a key to treatment effectiveness
- 11:30 ALBRECHT ULMER (Stuttgart, Germany) The central importance of trust and confidence in the treatment of addictions
- 12:00 RIK BES (Hilversum, The Netherlands) Addiction and motivation: what works?
- 12:30 RAGNHILD KJOSNES (Oslo, Norway) Treatment of trauma and dissociation in opioid dependent patients

Room: A - Parallel Symposia

VII - Treating Opioid-dependent Women: New Horizons
Chairman I. O. Lund (Oslo - Norway) and H. Jones (Research Triangle Park, NC, USA)

- 14:30 INGUNN OLEA LUND (Oslo, Norway) Pregnant women in opioid maintenance treatment in Norway: prescription drug use before and during pregnancy
- 15:00 IRMA KIRTADZE (Tbilisi, Georgia) Developing women-specific drug treatment services in Georgia: Understanding the barriers to treatment
- 15:30 MARJORIE MEYER (Burlington, Vermont, VR, USA) Induction onto Buprenorphine during Pregnancy: Evidence from Real Life Experience

16:00 KAROL KALTENBACH (Philadelphia, USA) - The MOTHER study: Withdrawal during induction and dosing profiles of methadone and buprenorphine across trimesters

Room: B - Parallel Symposia

VIII - Drug related mortality in Europe Chairman (Linn Gjersing –Oslo, Norway)

- 14:30 BENGT EIDE-OLSEN (Bergen, Norway) Opiate addiction, Regulated substitution and associated deaths. The likely importance of a high threshold in an environment with elevated detoxification pressure. Norway 1990-2010
- 15:00 LINN GJERSING (Oslo, Norway) Three years overdose mortality in Oslo. An investigation of types of overdose deaths and preventive efforts in a high level city. What went wrong and what can be done?
- 15:30 MARCEL BUSTER (Amsterdam, The Netherlands) Estimation of number of lives saved. A analysis of benefits from injection room and other low threshold measures
- 16:00 ALESSANDRO PIRONA and ISABELLE GIRAUDON (Lisbon, Portugal) Current developments and future challenges in addressing drug-related deaths in Europe

Room: C - Parallel Symposia

IX - Can genetics help in Opioid Treatment? Chairman M. Torrens (Barcelona - Spain)

- 14:30 MARTA TORRENS (Barcelona, Spain) Utilization of pharmacogenomics for methadone management
- 15:00 CHIN EAP (Prilly-Lausanne, Switzerland) Genetics of methadone pharmacokinetics and cardiotoxicity: an update
- 15:30 JOSÉ PEREZ DE LOS COBOS (Barcelona, Spain) 2D6 genetic polymorphisms and patient satisfaction with methadone maintenance treatment
- 16:00 FRANCINA FONSECA (Barcelona, Spain) Pharmacodynamic genetic variability and response to methadone maintenance treatment

Room: A - Parallel Symposia

X - European Quality Audit of Opioid Treatment (EQUATOR): Insights on the current state of treatment provision in Europe

Chairman H. Stöver (Frankfurt - Germany)

- 17:00 HEINO STÖVER (Frankfurt, Germany) Variation in treatment delivery and outcomes across Europe What are the knowledge gaps?
- 17:30 GABRIELE FISCHER (Vienna, Austria) How does the quality of patient care vary across Europe?
- 18:00 ANNETTE DALE-PERERA (London, United Kingdom) How do patient and public health outcomes vary across Europe?
- 18:30 AMINE BENYAMINA (Paris, France) How has public policy shaped clinical practice across Europe? Case studies from the EQUATOR project

Room: B - Parallel Symposia

XI - OMT with buprenorphine+naloxone State of the art Clinical practices in Portugal, France and Spain

Chairman L. Patricio (Lisbon - Portugal)

- 17:00 DIDIER TOUZEAU (Paris, France) Buprenorphine/naloxone (Suboxone®) in France : Long is the road, first step.
- 17:30 PASCAL COURTY (Clermont Ferrand, France) Buprenorphine/naloxone (Suboxone®) in France: Long is the road, second step.
- 18:00 ANTONIO TERAN (Palencia, Spain) Opiate Addiction Treatment with Buprenorphine-Naloxone: current situation in Spain. An unquestionable reality
- 18:30 LUIS PATRICIO (Lisbon, Portugal) Opiate Maintenance Treatment: understanding and promoting the best treatments. Buprenorphine+ Naloxone, 5 years of clinical practice.

Room: C - Parallel Symposia

XII - Is it possible to treat psychopathology of heroin addicts only with AOT Chairman P. P. Pani (Cagliari - Italy)

- 17:00 PIER PAOLO PANI (Cagliari, Italy) Does the prominent psychopathology of heroin addicts exist?
- 17:30 ICRO MAREMMANI (Pisa, Italy) What is the specific psychopathology of Heroin Addicts at treatment entry?
- 18:00 LUCA ROVAI (Pisa, Italy) Affective temperaments and substance abuse
- 18:30 ANGELO GIOVANNI ICRO MAREMMANI (Pisa, Italy) Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?

Sunday, May 27 2012

Room: A - Plenary Session

Chairman A. Kastelic (Ljubljana - Slovenia)

9:30 HANNU ALHO (Helsinki, Finland) - Strategies to reduce the diversion of maintenance medications

Room: A - Parallel Symposia

XIII - SEEA-Symposium

Chairman A. Kastelic (Ljubljana - Slovenia)

- 11:00 LILJANA IGNJATOVA (Skopje, Republic of Macedonia) Insomnia in patients maintained with methadone
- 11:30 NUSA SEGREC (Ljubljana, Slovenia)- Challenges in Treatment of Patients with Complex

- Needs in Slovenia
- 12:00 ANTE IVANCIC (Porec. Croatia) Twenty years of OMT in Croatia no threshold, decentralized and successful
- 12:30 ANDREJ KASTELIC (Ljubljana, Slovenia) Developing treatment programs in communities and prisons in SE Europe

Room: B - Parallel Symposia

XIV - Heroin Addiction and Related Clinical Problems Chairman I. Demaret (Liège - Belgium)

- 11:00 JOSÈ PÉREZ DE LOS COBOS (Barcelona, Spain) Psychometric properties of the Cocaine Selective Severity Assessment in cocaine-dependent methadone-maintained patients
- 11:30 MARTA TORRENS (Barcelona, Spain) Development of a group intervention to reduce intimate partner violence among female drug users. A pilot study in two outpatient drug dependency centres
- 12:00 JEĻENA KOĻESŅĪKOVA (Riga, Latvia) Relationship of drug-addicted patients' personality disorders to social problem-solving changes during the rehabilitation process.
- 12:30 ISABELLE DEMARET (Liège, Belgium) Did the Belgian heroin-assisted treatment, TADAM, included the expected target group of severe heroin addicts?

Room: C - Parallel Symposia

XV – Heroin Addiction and Related Clinical Problems Chairman L. Somaini (Biella-Italy)

- 11:00 LORENZO SOMAINI (Biella, Italy) Buprenorphine and naltrexone combination in the treatment of cocaine dependence
- 11:30 PIETRO CASELLA (Rome, Italy) A comparison of socio-demographics and clinical status between native Italian and immigrant opiate dependent.
- 12:00 PIERGIOVANNI MAZZOLI (Fano, PU, Italy) Key elements to guide the choice of drug treatment in heroin addiction
- 12:30 MARC REISINGER (Bruxelles, Belgium) How should Methadone and Buprenorphine-Treatment be organized and regulated? A comparison of two systems in the context of a Europad-conference in Brussels